- Category: News
The Idiopathic Pulmonary Fibrosis Week was created in 2012 as an initiative to inform people around the globe that Idiopathic Pulmonary Fibrosis (IPF) is a rare and poorly understood chronic and ultimately fatal lung disease. Each year, around 35,000 people in Europe are newly diagnosed with IPF, with this number likely to increase in the future. This year the World IPF Week will take place from 5 to 11 October 2015!
- Category: News
For the first time, IPF patient advocacy groups came together to develop a European IPF Charter in support of more standardised care and equal access to diagnosis, treatment and after care options for those with IPF in Europe. The Charter has been endorsed my medical experts who are actively involved in IPF management and we are currently approaching various stakeholders to secure additional endorsement.
- Category: IPF
What is Idiopathic Pulmonary Fibrosis?
“Idiopathic” means unknown – no one knows the exact cause of IPF. What is understood is that, with IPF, there is a change in the lung’s normal healing process that produces extra scar tissue. Unfortunately, there are no symptoms of this change until the scar tissue builds up in the lungs and affects breathing. The causes of this abnormal healing process are unknown, but there are a number of factors that may be associated with an increased risk of developing IPF.
Potential risk factors associated with IPF
Cigarette smoking may increase the risk of developing IPF. Some cases of IPF occur in patients who have family members with IPF, which suggests that genetics may contribute to the risk of developing IPF in certain individuals. Although these risk factors are associated with IPF, it is important to remember that they have not been shown to cause IPF − the cause of the disease is still unknown.